Bengaluru-based biopharmaceutical company Biocon Limited has announced its Q4 FY24 results, reporting a significant 56.7% decline in consolidated profits, which fell to ₹135.5 crore from ₹313.2 crore in the same quarter last year. Siddharth Mittal, CEO & Managing Director of Biocon Limited, discussed the performance and future outlook of the company's three main business segments—Biosimilars, Generics, and Research Services—in an interview with businessline. Mittal elaborated on the strategic roadmaps planned for each segment to address current challenges and drive future growth.
HBL
This site is best viewed with a resolution of 1024x768 (or higher) and supports Microsoft Internet Explorer 4.0 (or higher)
Copyright © 2016-2025
Premium Projects Database
Project Marketing Assistance
EPXonline.com 
